In that respect, Hanagata et al. [36] have investigated whether in vivo treatment with FK506 in a model of OI type V could inhibit Ifitm5 expression, and/or its interaction with FKBP11 that they had previously identified [25]. The gene discussed is FKBP11; the disease is osteogenesis imperfecta type 5.